<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="prp270080" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11850437</article-id><article-id pub-id-type="pmcid-ver">PMC11850437.1</article-id><article-id pub-id-type="pmcaid">11850437</article-id><article-id pub-id-type="pmcaiid">11850437</article-id><article-id pub-id-type="pmid">39995024</article-id><article-id pub-id-type="doi">10.1002/prp2.70080</article-id><article-id pub-id-type="publisher-id">PRP270080</article-id><article-id pub-id-type="other">PRP2-2025-01-0029.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Analysis of Reporting Trends of Serious Adverse Events Associated With Anti&#8208;Obesity Drugs</article-title></title-group><contrib-group><contrib id="prp270080-cr-0001" contrib-type="author"><name name-style="western"><surname>Rai&#269;evi&#263;</surname><given-names initials="BB">Branislava B.</given-names></name><xref rid="prp270080-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270080-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Belan&#269;i&#263;</surname><given-names initials="A">Andrej</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7848-6600</contrib-id><xref rid="prp270080-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>andrej.belancic@uniri.hr</email><email>a.belancic93@gmail.com</email></address></contrib><contrib id="prp270080-cr-0003" contrib-type="author"><name name-style="western"><surname>Mirkovi&#263;</surname><given-names initials="N">Nikola</given-names></name><xref rid="prp270080-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270080-cr-0004" contrib-type="author"><name name-style="western"><surname>Jankovi&#263;</surname><given-names initials="SM">Slobodan M.</given-names></name><xref rid="prp270080-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="prp270080-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of Kragujevac, Faculty of Medical Sciences</institution>
<city>Kragujevac</city>
<country country="RS">Serbia</country>
</aff><aff id="prp270080-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Basic and Clinical Pharmacology and Toxicology</named-content>
<institution>University of Rijeka, Faculty of Medicine</institution>
<city>Rijeka</city>
<country country="HR">Croatia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Andrej Belan&#269;i&#263; (<email>andrej.belancic@uniri.hr</email>; <email>a.belancic93@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>13</volume><issue seq="43">2</issue><issue-id pub-id-type="pmc-issue-id">482642</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v13.2</issue-id><elocation-id>e70080</elocation-id><history><date date-type="rev-recd"><day>13</day><month>2</month><year>2025</year></date><date date-type="received"><day>17</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-16 00:25:32.250"><day>16</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-13-e70080.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-13-e70080.pdf"/><abstract><title>ABSTRACT</title><p>Concern over the side effects of anti&#8208;obesity medications, particularly if severe, has grown as their use has increased. Thus, the objective was to use trends in the reporting of suspected adverse events associated with anti&#8208;obesity medications that have been approved for sale in the European Union to attempt to uncover discrepancies in the safety of these medications. The study was designed as secondary research, based on data about the number of adverse drug reactions (both serious and non&#8208;serious) reported to the EudraVigilance database. Trends of the annual reporting rates for the six anti&#8208;obesity drugs were analyzed by the Joinpoint Trend Analysis Software that divides the trendline into an optimum number of segments connected by &#8220;joinpoints&#8221; and tests the significance of the trend within each segment. The trends of serious adverse drug events showed clear differences among the anti&#8208;obesity drugs: while all drugs had significant increasing trends during a few initial years after their appearance on the market, only the annual number of reports for semaglutide continued to grow ever since (annual change&#8201;+&#8201;67.1%, <italic toggle="no">p</italic>&#8201;=&#8201;0.000). On the contrary, a continuous increase in the reporting rate of non&#8208;serious adverse drug events was observed only for liraglutide (annual change&#8201;+&#8201;33.8%, <italic toggle="no">p</italic>&#8201;=&#8201;0.000) while for the other anti&#8208;obesity drugs, including semaglutide, the trends after the initial period were either negative or did not increase significantly. In conclusion, among the anti&#8208;obesity drugs currently approved, only semaglutide shows a continuously increasing trend in the annual reporting of serious adverse events, suggesting a need for further investigation of safety signals.</p></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="prp270080-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-13-e70080-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp270080-kwd-0001">anti&#8208;obesity drugs</kwd><kwd id="prp270080-kwd-0002">semaglutide</kwd><kwd id="prp270080-kwd-0003">serious adverse drug events</kwd><kwd id="prp270080-kwd-0004">trends analysis</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="6"/><word-count count="3500"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:15.03.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="prp270080-body-0001"><sec id="prp270080-sec-0001"><label>1</label><title>Introduction</title><p>Although numerous substances were used for the treatment of obesity in the past [<xref rid="prp270080-bib-0001" ref-type="bibr">1</xref>], currently, there are six active principles having marketing authorization in countries of the European Union as anti&#8208;obesity medications: orlistat, semaglutide, liraglutide, naltrexone/bupropion, tirzepatide, and setmelanotide. The long&#8208;acting <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=29" ext-link-type="uri">glucagon&#8208;like peptide&#8208;1 receptor</ext-link> agonists (GLP&#8208;1RAs) liraglutide and semaglutide are also potent anti&#8208;diabetic agents. In patients with diabetes mellitus Type 2, liraglutide and semaglutide slow gastric emptying, stimulate glucose&#8208;dependent insulin secretion, improve beta&#8208;cell function, and decrease secretion of glucagon, leading to improved control of glycemia together with weight loss [<xref rid="prp270080-bib-0002" ref-type="bibr">2</xref>, <xref rid="prp270080-bib-0003" ref-type="bibr">3</xref>]. Anti&#8208;obesity drugs are increasingly prescribed (in the United States of America anti&#8208;obesity drugs were prescribed to 1.1% of obese persons in 2010 and to 2.9% in 2019) [<xref rid="prp270080-bib-0004" ref-type="bibr">4</xref>], especially for women [<xref rid="prp270080-bib-0005" ref-type="bibr">5</xref>], and up to 8% of patients after bariatric surgery continue to use anti&#8208;obesity drugs [<xref rid="prp270080-bib-0006" ref-type="bibr">6</xref>]. European countries also witness a continuous increase in anti&#8208;obesity drug prescribing: from 1999 to 2006, the annual prevalence of anti&#8208;obesity drug prescriptions in the United Kingdom increased 15&#8208;fold [<xref rid="prp270080-bib-0007" ref-type="bibr">7</xref>], and from 2017 to 2022 in Norway, 2.8% of the adults were prescribed an anti&#8208;obesity drug. In 2022, 1.04% of the adults in Norway used bupropion&#8208;naltrexone, 0.91% used liraglutide, and 0.68% semaglutide [<xref rid="prp270080-bib-0008" ref-type="bibr">8</xref>]. About 10% of Italian endocrinologists prescribe liraglutide as the main treatment for their obese patients [<xref rid="prp270080-bib-0009" ref-type="bibr">9</xref>].</p><p>Parallel with increasing utilization of anti&#8208;obesity drugs, there is growing concern about their adverse effects. A recent systematic review of clinical trials with anti&#8208;obesity drugs found higher rates of drug discontinuation due to adverse effects with naltrexone&#8208;bupropion, glucagon&#8208;like peptide&#8212;1 receptor agonists, and orlistat than with other anti&#8208;obesity drugs [<xref rid="prp270080-bib-0010" ref-type="bibr">10</xref>]. Analysis of the FDA Adverse Event Reporting System (FAERS) databases for the period 2013&#8211;2020 showed that as many as 18,675 reports of adverse events were associated with anti&#8208;obesity drugs prescribed to 15,143 patients [<xref rid="prp270080-bib-0011" ref-type="bibr">11</xref>]. It is especially worrying that more than 90% of adverse events associated with anti&#8208;obesity drugs and spontaneously reported to the European adverse events database were characterized as serious [<xref rid="prp270080-bib-0012" ref-type="bibr">12</xref>].</p><p>Many aspects of the adverse effects of anti&#8208;obesity drugs remain unclear, especially when serious but rare adverse effects are in question. Recently, one of the anti&#8208;obesity drugs (lorcaserin) was withdrawn from the market due to its association with increased occurrence of cancer, but it took more than 8&#8201;years of lorcaserin's widespread use to recognize the extent of the risk [<xref rid="prp270080-bib-0013" ref-type="bibr">13</xref>]. Analyzing trends of reporting adverse events of some drugs (e.g., of antidepressants) was helpful for the recognition of signals ultimately leading to an update of their safety profile&#160;[<xref rid="prp270080-bib-0014" ref-type="bibr">14</xref>]. When the increasing trend of spontaneous adverse drug reaction reports in Germany from 2000 to 2019 was compared with trends of the German population as a whole and the subpopulation of children, it was possible to identify changes in the administrative regulation of spontaneous reporting as a likely cause [<xref rid="prp270080-bib-0015" ref-type="bibr">15</xref>].</p><p>Our research's objective was to use trends in the reporting of suspected adverse events associated with anti&#8208;obesity medications that have been approved for sale in the European Union to attempt to uncover discrepancies in the safety of these medications.</p></sec><sec sec-type="materials-and-methods" id="prp270080-sec-0002"><label>2</label><title>Materials and Methods</title><p>The study was designed as secondary research, based on data about the number of adverse drug reactions (both serious and non&#8208;serious) reported to the EudraVigilance&#8212;European database of suspected adverse drug reports, established and maintained by the European Medicines Agency (EMA) from 2002 onward [<xref rid="prp270080-bib-0016" ref-type="bibr">16</xref>]. Since ethics committee approval was not necessary for this kind of research, it was not requested.</p><p>The suspected adverse drug reports were analyzed for six drugs that have the treatment of obesity as one of the approved indications in countries of the European Union: orlistat, semaglutide, liraglutide, naltrexone/bupropion, tirzepatide, and setmelanotide. The outcome variables in the study were the counts of serious adverse drug reactions (SADRs) and non&#8208;serious adverse drug reactions (nSADRs) per calendar year (annual reporting rate), starting from the moment when reporting to EudraVigilance started. The independent variable was the reporting year. The counts of both SADRs and nSADRs are aggregate data, including all spontaneous reports in the database, regardless of the adverse drug reaction type; such an approach implies that the figures represent more overall attention of prescribers that these drugs captured than certain specific adverse effect mechanisms.</p><p>Trends of the annual reporting rates for the six drugs were analyzed by the Joinpoint Trend Analysis Software, version 5.2.0, issued and maintained by the National Cancer Institute of the USA [<xref rid="prp270080-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270080-bib-0018" ref-type="bibr">18</xref>]. This is the regression software that divides the trendline into an optimum number of segments connected by &#8220;joinpoints&#8221;, and tests the significance of the trend within each of the segments. The significance of the trends is tested by a Monte Carlo Permutation method, and the annual percent change of the rates is calculated. The significance level was set at&#8201;&#8804;&#8201;0.05 probability of the null hypothesis.</p></sec><sec sec-type="results" id="prp270080-sec-0003"><label>3</label><title>Results</title><p>Trends of counts of suspected adverse drug reactions (SADR) per year were analyzed for six anti&#8208;obesity drugs: orlistat, semaglutide, liraglutide, naltrexone/bupropion, tirzepatide, and setmelanotide, for the years 2002&#8211;2024, depending on the availability of the data in Eudravigilance&#8212;European database. The data were extracted from the database on September 16th, 2024. The trends of serious SADRs are shown in Figure&#160;<xref rid="prp270080-fig-0001" ref-type="fig">1</xref>, and those of non&#8208;serious SADRs are presented in Figure&#160;<xref rid="prp270080-fig-0002" ref-type="fig">2</xref>. The annual percent change of the counts and the significance of the trends for each drug are shown in Tables&#160;<xref rid="prp270080-tbl-0001" ref-type="table">1</xref> and <xref rid="prp270080-tbl-0002" ref-type="table">2</xref> (serious SADRs and non&#8208;serious SADRs, respectively).</p><fig position="float" fig-type="FIGURE" id="prp270080-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Trends in reporting serious adverse events associated with anti&#8208;obesity medications.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-13-e70080-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="prp270080-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Trends of reporting non&#8208;serious adverse events associated with anti&#8208;obesity medications.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-13-e70080-g003.jpg"/></fig><table-wrap position="float" id="prp270080-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Trend segments, annual percent change, and significance of the trend segments for Serious Suspected Adverse Drug Reactions (SADRs).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Medicine</th><th align="center" valign="bottom" rowspan="1" colspan="1">Trend segment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Annual percent change (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="2" valign="top" colspan="1">Orlistat</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">41.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.080</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;14.1</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.019</bold>
</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Liraglutide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">611.8</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Semaglutide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">67.1</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Naltrexone/Bupropion</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">203.8</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.007</bold>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">9.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.689</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tirzepatide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">232.6</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setmelanotide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">173.9</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="prp270080-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Trend segments, annual percent change, and significance of the trend segments for Non&#8208;Serious Suspected Adverse Drug Reactions (SADRs).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Medicine</th><th align="center" valign="bottom" rowspan="1" colspan="1">Trend segment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Annual Percent Change (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="2" valign="top" colspan="1">Orlistat</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">512.4</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.012</bold>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">5.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.402</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Liraglutide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">281.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.227</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">33.8</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Semaglutide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1079.0</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">11.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.917</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Naltrexone/Bupropion</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">215.5</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.914</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tirzepatide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1621.9</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setmelanotide</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">307.4</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr></tbody></table></table-wrap><p>Trends for serious SADRs of orlistat, liraglutide, and naltrexone/bupropion exhibited two segments each, the initial one showing a sharp increase for all drugs, and the second showing either a decrease or insignificant increase for orlistat, liraglutide, and naltrexone/bupropion. Trends for serious SADRs of semaglutide, tirzepatide, and setmelanotide had only one segment, sharply and significantly increasing, but data for only 3&#8201;years were available for the last two drugs (Figure&#160;<xref rid="prp270080-fig-0001" ref-type="fig">1</xref> and Table&#160;<xref rid="prp270080-tbl-0001" ref-type="table">1</xref>). Trends for non&#8208;serious SADRs of orlistat, liraglutide, semaglutide, and naltrexone/bupropion also exhibited two segments each, the initial one showing a sharp increase for all drugs, and the second showing either a decrease or insignificant increase for orlistat, semaglutide, and naltrexone/bupropion, while for liraglutide, the second trend segment was significantly increasing. Trends for non&#8208;serious SADRs of tirzepatide and setmelanotide also had only one segment, sharply and significantly increasing, due to limited data availability (only 3&#8201;years) (Figure&#160;<xref rid="prp270080-fig-0002" ref-type="fig">2</xref> and Table&#160;<xref rid="prp270080-tbl-0002" ref-type="table">2</xref>).</p><p>Available proprietary preparations of orlistat, semaglutide, liraglutide, naltrexone/bupropion, tirzepatide, and setmelanotide, their marketing authorization dates, and onset of SADRs reporting to Eudravigilance are shown in Table&#160;<xref rid="prp270080-tbl-0003" ref-type="table">3</xref>. Furthermore, the most frequently reported AEs associated with anti&#8208;obesity drugs are presented in Table&#160;<xref rid="prp270080-tbl-0004" ref-type="table">4</xref>.</p><table-wrap position="float" id="prp270080-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Regulatory and SADRs reporting data for six antiobesity drugs.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Proprietary/non&#8208;proprietary name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Therapeutic area</th><th align="center" valign="bottom" rowspan="1" colspan="1">ATC code</th><th align="center" valign="bottom" rowspan="1" colspan="1">Marketing authorization date</th><th align="center" valign="bottom" rowspan="1" colspan="1">First reporting of SADRs</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total SADRs</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Saxenda</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity; Overweight</td><td align="center" valign="top" rowspan="1" colspan="1">A10BJ02</td><td align="center" valign="top" rowspan="1" colspan="1">23/03/2015</td><td align="center" valign="top" rowspan="1" colspan="1">07/06/2015</td><td align="center" valign="top" rowspan="1" colspan="1">5843</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Victoza</td><td align="center" valign="top" rowspan="1" colspan="1">Diabetes Mellitus, Type 2</td><td align="center" valign="top" rowspan="1" colspan="1">A10BJ02</td><td align="center" valign="top" rowspan="1" colspan="1">30/06/2009</td><td align="center" valign="top" rowspan="1" colspan="1">09/08/2009</td><td align="center" valign="top" rowspan="1" colspan="1">1&#8201;2450</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lilraglutide (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A10BJ02</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">29/01/2009</td><td align="center" valign="top" rowspan="1" colspan="1">18922</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mysimba</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity; Overweight</td><td align="center" valign="top" rowspan="1" colspan="1">A08AA</td><td align="center" valign="top" rowspan="1" colspan="1">26/03/2015</td><td align="center" valign="top" rowspan="1" colspan="1">21/03/2017</td><td align="center" valign="top" rowspan="1" colspan="1">880</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naltrexone/bupropion (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A08AA</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">12/01/2014</td><td align="center" valign="top" rowspan="1" colspan="1">2236</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Alli (previously Orlistat GSK)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity</td><td align="center" valign="top" rowspan="1" colspan="1">A08AB01</td><td align="center" valign="top" rowspan="1" colspan="1">22/07/2007</td><td align="center" valign="top" rowspan="1" colspan="1">14/08/2007</td><td align="center" valign="top" rowspan="1" colspan="1">1100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Xenical</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity</td><td align="center" valign="top" rowspan="1" colspan="1">A08AB01</td><td align="center" valign="top" rowspan="1" colspan="1">29/07/1998</td><td align="center" valign="top" rowspan="1" colspan="1">24/01/2003</td><td align="center" valign="top" rowspan="1" colspan="1">3603</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Orlistat (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A08AB01</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">24/01/2003</td><td align="center" valign="top" rowspan="1" colspan="1">5380</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ozempic</td><td align="center" valign="top" rowspan="1" colspan="1">Diabetes Mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">A10BJ06</td><td align="center" valign="top" rowspan="1" colspan="1">08/02/2018</td><td align="center" valign="top" rowspan="1" colspan="1">22/02/2018</td><td align="center" valign="top" rowspan="1" colspan="1">18649</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rybelsus</td><td align="center" valign="top" rowspan="1" colspan="1">Diabetes Mellitus, Type 2</td><td align="center" valign="top" rowspan="1" colspan="1">A10BJ06</td><td align="center" valign="top" rowspan="1" colspan="1">03/04/2020</td><td align="center" valign="top" rowspan="1" colspan="1">01/09/2020</td><td align="center" valign="top" rowspan="1" colspan="1">3435</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wegovy</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity; Overweight</td><td align="center" valign="top" rowspan="1" colspan="1">A10BJ06</td><td align="center" valign="top" rowspan="1" colspan="1">06/01/2022</td><td align="center" valign="top" rowspan="1" colspan="1">01/12/2022</td><td align="center" valign="top" rowspan="1" colspan="1">1579</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Semaglutide (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A10BJ06</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">01/03/2018</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8201;6727</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Imcivree</td><td align="center" valign="top" rowspan="1" colspan="1">Obesity</td><td align="center" valign="top" rowspan="1" colspan="1">A08AA</td><td align="center" valign="top" rowspan="1" colspan="1">16/07/2021</td><td align="center" valign="top" rowspan="1" colspan="1">15/06/2022</td><td align="center" valign="top" rowspan="1" colspan="1">159</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setmelanotide (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A08AA</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">15/06/2022</td><td align="center" valign="top" rowspan="1" colspan="1">159</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mounjaro</td><td align="center" valign="top" rowspan="1" colspan="1">Diabetes Mellitus, Type 2; Obesity; Overweight</td><td align="center" valign="top" rowspan="1" colspan="1">A10BX16</td><td align="center" valign="top" rowspan="1" colspan="1">15/09/2022</td><td align="center" valign="top" rowspan="1" colspan="1">22/07/2022</td><td align="center" valign="top" rowspan="1" colspan="1">4327</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mounjaro Kwikpen</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A10BX16</td><td align="center" valign="top" rowspan="1" colspan="1">15/09/2022</td><td align="center" valign="top" rowspan="1" colspan="1">23/04/2024</td><td align="center" valign="top" rowspan="1" colspan="1">60</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tirzepatide (INN)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">A10BX16</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">22/07/2022</td><td align="center" valign="top" rowspan="1" colspan="1">4631</td></tr></tbody></table></table-wrap><table-wrap position="float" id="prp270080-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Most frequently reported adverse events (AEs) associated with anti&#8208;obesity drugs.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Drug</th><th align="center" valign="bottom" rowspan="1" colspan="1">The most frequently reported adverse drug reactions</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Orlistat</td><td align="center" valign="top" rowspan="1" colspan="1">Fatty/oily stool, abdominal pain, abdominal distension, increased defecation, respiratory infection, headache, hypoglycemia</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Semaglutide</td><td align="center" valign="top" rowspan="1" colspan="1">Nausea, vomiting, diarrhea, abdominal pain, constipation, decreased appetite, hypoglicemia, fatigue</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liraglutide</td><td align="center" valign="top" rowspan="1" colspan="1">Nausea, vomiting, diarrhea, abdominal pain, constipation, insomnia, hypoglicemia, rash</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Naltrexone/Bupropion</td><td align="center" valign="top" rowspan="1" colspan="1">Anxiety, insomnia, headache, tremor, dysgeusia, somnolence, tinnitus, palpitations, nausea, constipation, dry mouth, hyperhidrosis, fatigue</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tirzepatide</td><td align="center" valign="top" rowspan="1" colspan="1">Nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence, hypersensitivity reactions, hypoglicemia, fatigue, hair loss</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setmelanotide</td><td align="center" valign="top" rowspan="1" colspan="1">Injection site reactions, hyperpigmentation, spontaneous erections, nausea, vomiting, headache, polydipsia, back pain, pruritus, depression</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="prp270080-sec-0004"><label>4</label><title>Discussion</title><p>The trends of serious adverse drug events showed clear differences among the anti&#8208;obesity drugs: while all drugs had a significant increasing trend during a few initial years after their appearance on the market, only the annual number of reports for semaglutide continued to grow ever since. The reporting rates for the other five anti&#8208;obesity drugs were either decreasing or without significant increases. On the contrary, a continuous increase in the reporting rate of non&#8208;serious adverse drug events was observed only for liraglutide, while for the other anti&#8208;obesity drugs, including semaglutide, the trend after the initial period was either negative or did not increase significantly.</p><p>One of the possible causes of the continuous increase in the reporting rate of serious adverse events associated with semaglutide use could be a constant increase in utilization, which was observed in some countries. In the United States of America, semaglutide was the third top&#8208;selling drug in 2023 and became the first top&#8208;selling drug in 2024 [<xref rid="prp270080-bib-0019" ref-type="bibr">19</xref>, <xref rid="prp270080-bib-0020" ref-type="bibr">20</xref>]; semaglutide prescriptions increased in numbers by 442% between January 2021 and December 2023 [<xref rid="prp270080-bib-0021" ref-type="bibr">21</xref>]. However, in Europe, where this study was conducted, liraglutide and naltrexone/bupropion were prescribed more frequently than semaglutide in 2022: 1.04% of adults in Norway were using naltrexone/bupropion, 0.91% liraglutide, and only 0.68% semaglutide [<xref rid="prp270080-bib-0008" ref-type="bibr">8</xref>]. Besides, if the continuously increasing trend of serious adverse events associated with semaglutide was a consequence of increased prescribing, one could expect that non&#8208;serious adverse events would be increasingly reported, too; but this was not the case in our study.</p><p>When an increasing trend of utilization of certain drugs is associated with a decreasing trend of reporting serious adverse events, this points to a good safety profile of such drugs and precludes the necessity for further observational pharmacovigilance studies, except for spontaneous reporting. An increasing trend of utilization of drugs for attention deficit hyperactivity disorder was observed in England while reporting of their serious and fatal ADRs dropped by 1.79% per year for the whole group except for guanfacine, which showed a 40% annual increase [<xref rid="prp270080-bib-0022" ref-type="bibr">22</xref>]. A similar situation was observed for metformin and new oral anticoagulants, whose utilization increased, but the adverse events reporting rate decreased [<xref rid="prp270080-bib-0023" ref-type="bibr">23</xref>, <xref rid="prp270080-bib-0024" ref-type="bibr">24</xref>]. However, if the opposite happens, one could expect to discover some adverse effect signal that is in the background of the increasing trend of adverse events reporting.</p><p>In the study of adverse events reporting rate trends (2004&#8211;2021) associated with the use of selective serotonin reuptake inhibitors (SSRI) significantly increasing trends were observed for arrhythmias and QT interval prolongation. Further disproportionality analysis of the same database confirmed the existence of signals for arrhythmias and QT interval prolongation for all investigated SSRIs [<xref rid="prp270080-bib-0014" ref-type="bibr">14</xref>]. This example underlines the importance of analyzing adverse drug events reporting trends as a pilot for the initiation of investigating signals. We should also bear in mind that serious adverse drug reactions become more readily spotted only several years after marketing authorization approval, due to their inherent rarity and idiosyncrasy [<xref rid="prp270080-bib-0025" ref-type="bibr">25</xref>]. Whether the increasing trend of semaglutide serious adverse events reporting observed in our study is linked to some safety signal(s) remains to be explored in future studies.</p><p>There are several limitations of our study. First, only one adverse event reporting database was used for analysis, which may introduce bias due to specific construction characteristics of that database, different from others. Second, not all anti&#8208;obesity drugs could have been followed for a sufficient number of years (due to their recent marketing authorization) decreasing the overall statistical power of the trend analysis. Third, the database analyzed did not have the option to construct separate trends according to the approved indications for which the drugs were used, which caused clumping of the adverse event reports and possible bias due to possible off&#8208;label use of some of the drugs.</p><p>In conclusion, among the anti&#8208;obesity drugs currently approved, only semaglutide shows a continuously increasing trend of annual reporting of serious adverse events, suggesting a need for further investigation of safety signals.</p></sec><sec id="prp270080-sec-0008"><title>Author Contributions</title><p>Project administration: Andrej Belan&#269;i&#263;, Slobodan M. Jankovi&#263;. Methodology: Slobodan M. Jankovi&#263;, Branislava B. Rai&#269;evi&#263;. Investigation: Slobodan M. Jankovi&#263;, Andrej Belan&#269;i&#263;, Branislava B. Rai&#269;evi&#263;, Nikola Mirkovi&#263;. Writing &#8211; original draft: Branislava B. Rai&#269;evi&#263;, Slobodan M. Jankovi&#263;. Writing &#8211; review and editing: Branislava B. Rai&#269;evi&#263;, Andrej Belan&#269;i&#263;, Nikola Mirkovi&#263;, Slobodan M. Jankovi&#263;. Conceptualization: Slobodan M. Jankovi&#263;. Supervision: Slobodan M. Jankovi&#263;. All authors have read and agreed to the published version of the manuscript.</p></sec><sec id="prp270080-sec-0007"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="prp270080-sec-0009"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="prp270080-sec-0010"><title>Acknowledgments</title><p>The authors have nothing to report. Open access publishing facilitated by Sveuciliste u Rijeci, as part of the Wiley &#8208; National and University Library in Zagreb Consortium Croatian Academic and Research Libraries Consortium agreement.</p></ack><sec sec-type="data-availability" id="prp270080-sec-0006"><title>Data Availability Statement</title><p>Available upon reasonable request sent to the corresponding author.</p></sec><ref-list content-type="cited-references" id="prp270080-bibl-0001"><title>References</title><ref id="prp270080-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp270080-cit-0001"><string-name name-style="western"><given-names>T.</given-names><surname>Yj</surname></string-name> and <string-name name-style="western"><given-names>L.</given-names><surname>Sy</surname></string-name>, &#8220;<article-title>Long&#8208;Term Efficacy and Safety of Anti&#8208;Obesity Treatment: Where Do we Stand?</article-title>,&#8221; <source>Current Obesity Reports</source><volume>10</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>14</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">33410104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13679-020-00422-w</pub-id><pub-id pub-id-type="pmcid">PMC7787121</pub-id></mixed-citation></ref><ref id="prp270080-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp270080-cit-0002"><string-name name-style="western"><given-names>D.</given-names><surname>Bataille</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Delagrange</surname></string-name>, et&#160;al., &#8220;<article-title>Glucagon Receptor Family in GtoPdb v. 2023.1</article-title>,&#8221; <source>IUPHAR/BPS Guide to Pharmacology CITE</source><volume>2023</volume>, no. <issue>1</issue> (<year>2023</year>), <pub-id pub-id-type="doi">10.2218/gtopdb/F29/2023.1</pub-id>.</mixed-citation></ref><ref id="prp270080-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp270080-cit-0003"><string-name name-style="western"><given-names>L. B.</given-names><surname>Knudsen</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Lau</surname></string-name>, &#8220;<article-title>The Discovery and Development of Liraglutide and Semaglutide</article-title>,&#8221; <source>Front Endocrinol (Lausanne)</source><volume>10</volume> (<year>2019</year>): <elocation-id>155</elocation-id>.<pub-id pub-id-type="pmid">31031702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2019.00155</pub-id><pub-id pub-id-type="pmcid">PMC6474072</pub-id></mixed-citation></ref><ref id="prp270080-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp270080-cit-0004"><string-name name-style="western"><given-names>A.</given-names><surname>Elangovan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Shah</surname></string-name>, and <string-name name-style="western"><given-names>Z. L.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Pharmacotherapy for Obesity&#8212;Trends Using a Population Level National Database</article-title>,&#8221; <source>Obesity Surgery</source><volume>31</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>1105</fpage>&#8211;<lpage>1112</lpage>.<pub-id pub-id-type="pmid">32986169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11695-020-04987-2</pub-id></mixed-citation></ref><ref id="prp270080-bib-0005"><label>5</label><mixed-citation publication-type="book" id="prp270080-cit-0005"><string-name name-style="western"><given-names>J.</given-names><surname>Cawley</surname></string-name> and <string-name name-style="western"><given-names>J. A.</given-names><surname>Rizzo</surname></string-name>, &#8220;<part-title>One Pill Makes You Smaller: The Demand for Anti&#8208;Obesity Drugs</part-title>,&#8221; in <source>The Economics of Obesity</source>, ed. <person-group person-group-type="editor"><string-name name-style="western"><given-names>K.</given-names><surname>Bolin</surname></string-name></person-group> and <person-group person-group-type="editor"><string-name name-style="western"><given-names>J.</given-names><surname>Cawley</surname></string-name></person-group> (<publisher-name>Emerald Group Publishing Limited</publisher-name>, <year>2006</year>), <fpage>149</fpage>&#8211;<lpage>183</lpage>.<pub-id pub-id-type="pmid">19548552</pub-id></mixed-citation></ref><ref id="prp270080-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp270080-cit-0006"><string-name name-style="western"><given-names>S. A.</given-names><surname>Firkins</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Chittajallu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Flora</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yoo</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Simons&#8208;Linares</surname></string-name>, &#8220;<article-title>Utilization of Anti&#8208;Obesity Medications After Bariatric Surgery: Analysis of a Large National Database</article-title>,&#8221; <source>Obesity Surgery</source><volume>34</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>1415</fpage>&#8211;<lpage>1424</lpage>.<pub-id pub-id-type="pmid">38512645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11695-024-07181-w</pub-id></mixed-citation></ref><ref id="prp270080-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp270080-cit-0007"><string-name name-style="western"><given-names>R. M.</given-names><surname>Viner</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Hsia</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Neubert</surname></string-name>, and <string-name name-style="western"><given-names>I. C.</given-names><surname>Wong</surname></string-name>, &#8220;<article-title>Rise in Antiobesity Drug Prescribing for Children and Adolescents in the UK: A Population&#8208;Based Study</article-title>,&#8221; <source>British Journal of Clinical Pharmacology</source><volume>68</volume>, no. <issue>6</issue> (<year>2009</year>): <fpage>844</fpage>&#8211;<lpage>851</lpage>.<pub-id pub-id-type="pmid">20002078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03528.x</pub-id><pub-id pub-id-type="pmcid">PMC2810795</pub-id></mixed-citation></ref><ref id="prp270080-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp270080-cit-0008"><string-name name-style="western"><given-names>P. L.</given-names><surname>Ruiz</surname></string-name>, <string-name name-style="western"><given-names>&#216;.</given-names><surname>Karlstad</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>N&#248;kleby</surname></string-name>, et&#160;al., &#8220;<article-title>Pharmacological Treatment of Obesity in Adults in Norway 2004&#8211;2022</article-title>,&#8221; <source>Diabetes, Obesity &amp; Metabolism</source><volume>26</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>2102</fpage>&#8211;<lpage>2110</lpage>, <pub-id pub-id-type="doi">10.1111/dom.15515</pub-id>.<pub-id pub-id-type="pmid">38419410</pub-id></mixed-citation></ref><ref id="prp270080-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp270080-cit-0009"><string-name name-style="western"><given-names>M.</given-names><surname>Chianelli</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Busetto</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Attanasio</surname></string-name>, et&#160;al., &#8220;<article-title>Obesity Management: Attitudes and Practice of Italian Endocrinologists</article-title>,&#8221; <source>Front Endocrinol (Lausanne)</source><volume>13</volume> (<year>2023</year>): <elocation-id>1061511</elocation-id>.<pub-id pub-id-type="pmid">36733804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.1061511</pub-id><pub-id pub-id-type="pmcid">PMC9888662</pub-id></mixed-citation></ref><ref id="prp270080-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp270080-cit-0010"><string-name name-style="western"><given-names>Q.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Hao</surname></string-name>, et&#160;al., &#8220;<article-title>Pharmacotherapy for Adults With Overweight and Obesity: A Systematic Review and Network Meta&#8208;Analysis of Randomised Controlled Trials</article-title>,&#8221; <source>Lancet (London, England)</source><volume>403</volume>, no. <issue>10434</issue> (<year>2024</year>): <fpage>e21</fpage>&#8211;<lpage>e31</lpage>.<pub-id pub-id-type="pmid">38582569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00351-9</pub-id></mixed-citation></ref><ref id="prp270080-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp270080-cit-0011"><string-name name-style="western"><given-names>A.</given-names><surname>Alsuhibani</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Alrasheed</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gari</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Hincapie</surname></string-name>, and <string-name name-style="western"><given-names>J. J.</given-names><surname>Guo</surname></string-name>, &#8220;<article-title>Descriptive Analysis of Reported Adverse Events Associated With Anti&#8208;Obesity Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013&#8208;2020</article-title>,&#8221; <source>International Journal of Clinical Pharmacy</source><volume>44</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>172</fpage>&#8211;<lpage>179</lpage>.<pub-id pub-id-type="pmid">34564826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-021-01330-2</pub-id></mixed-citation></ref><ref id="prp270080-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp270080-cit-0012"><string-name name-style="western"><given-names>L.</given-names><surname>Aagaard</surname></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Hallgreen</surname></string-name>, and <string-name name-style="western"><given-names>E. H.</given-names><surname>Hansen</surname></string-name>, &#8220;<article-title>Serious Adverse Events Reported for Antiobesity Medicines: Postmarketing Experiences From the EU Adverse Event Reporting System EudraVigilance</article-title>,&#8221; <source>International Journal of Obesity</source><volume>40</volume>, no. <issue>11</issue> (<year>2016</year>): <fpage>1742</fpage>&#8211;<lpage>1747</lpage>.<pub-id pub-id-type="pmid">27478924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ijo.2016.135</pub-id></mixed-citation></ref><ref id="prp270080-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp270080-cit-0013"><string-name name-style="western"><given-names>Y. J.</given-names><surname>Tak</surname></string-name> and <string-name name-style="western"><given-names>S. Y.</given-names><surname>Lee</surname></string-name>, &#8220;<article-title>Anti&#8208;Obesity Drugs: Long&#8208;Term Efficacy and Safety: An Updated Review</article-title>,&#8221; <source>World Journal of Men's Health</source><volume>39</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>208</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5534/wjmh.200010</pub-id><pub-id pub-id-type="pmcid">PMC7994651</pub-id><pub-id pub-id-type="pmid">32202085</pub-id></mixed-citation></ref><ref id="prp270080-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp270080-cit-0014"><string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Fan</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Shi</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Luo</surname></string-name>, &#8220;<article-title>Cardiovascular Toxicity Induced by SSRIs: Analysis of Spontaneous Reports Submitted to FAERS</article-title>,&#8221; <source>Psychiatry Research</source><volume>326</volume> (<year>2023</year>): <elocation-id>115300</elocation-id>.<pub-id pub-id-type="pmid">37364503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2023.115300</pub-id></mixed-citation></ref><ref id="prp270080-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp270080-cit-0015"><string-name name-style="western"><given-names>S.</given-names><surname>Leitzen</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dubrall</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Toni</surname></string-name>, et&#160;al., &#8220;<article-title>Analysis of the Reporting of Adverse Drug Reactions in Children and Adolescents in Germany in the Time Period From 2000 to 2019</article-title>,&#8221; <source>PLoS One</source><volume>16</volume>, no. <issue>3</issue> (<year>2021</year>): <elocation-id>e0247446</elocation-id>.<pub-id pub-id-type="pmid">33657139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0247446</pub-id><pub-id pub-id-type="pmcid">PMC7928460</pub-id></mixed-citation></ref><ref id="prp270080-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="prp270080-cit-0016"><article-title>&#8220;European database of suspected adverse drug reaction reports [Internet].&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.adrreports.eu/en/index.html" ext-link-type="uri">https://www.adrreports.eu/en/index.html</ext-link>.</mixed-citation></ref><ref id="prp270080-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="prp270080-cit-0017"><article-title>&#8220;Joinpoint Regression Program, 2024&#8221;</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://surveillance.cancer.gov/joinpoint/" ext-link-type="uri">https://surveillance.cancer.gov/joinpoint/</ext-link>.</mixed-citation></ref><ref id="prp270080-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp270080-cit-0018"><string-name name-style="western"><given-names>H. J.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>Fay</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Feuer</surname></string-name>, and <string-name name-style="western"><given-names>D. N.</given-names><surname>Midthune</surname></string-name>, &#8220;<article-title>Permutation Tests for Joinpoint Regression With Applications to Cancer Rates</article-title>,&#8221; <source>Statistics in Medicine</source><volume>19</volume> (<year>2000</year>): <fpage>335</fpage>&#8211;<lpage>351</lpage>, <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0258(20000215)19:3&amp;#x0003c;&amp;#x0003e;3.0.co;2-z</pub-id>.<pub-id pub-id-type="pmid">10649300</pub-id></mixed-citation></ref><ref id="prp270080-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp270080-cit-0019"><string-name name-style="western"><given-names>E. M.</given-names><surname>Tichy</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hoffman</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tadrous</surname></string-name>, et&#160;al., &#8220;<article-title>National Trends in Prescription Drug Expenditures and Projections for 2023</article-title>,&#8221; <source>American Journal of Health&#8208;System Pharmacy</source><volume>80</volume>, no. <issue>14</issue> (<year>2023</year>): <fpage>899</fpage>&#8211;<lpage>913</lpage>.<pub-id pub-id-type="pmid">37094296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajhp/zxad086</pub-id></mixed-citation></ref><ref id="prp270080-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp270080-cit-0020"><string-name name-style="western"><given-names>E. M.</given-names><surname>Tichy</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hoffman</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Tadrous</surname></string-name>, et&#160;al., &#8220;<article-title>National Trends in Prescription Drug Expenditures and Projections for 2024</article-title>,&#8221; <source>American Journal of Health&#8208;System Pharmacy</source><volume>81</volume>, no. <issue>14</issue> (<year>2024</year>): <fpage>583</fpage>&#8211;<lpage>598</lpage>.<pub-id pub-id-type="pmid">38656319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajhp/zxae105</pub-id></mixed-citation></ref><ref id="prp270080-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp270080-cit-0021"><string-name name-style="western"><given-names>C.</given-names><surname>Scannell</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Romley</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Myerson</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Goldman</surname></string-name>, and <string-name name-style="western"><given-names>D. M.</given-names><surname>Qato</surname></string-name>, &#8220;<article-title>Prescription Fills for Semaglutide Products by Payment Method</article-title>,&#8221; <source>JAMA Health Forum</source><volume>5</volume>, no. <issue>8</issue> (<year>2024</year>): <elocation-id>e242026</elocation-id>.<pub-id pub-id-type="pmid">39093590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamahealthforum.2024.2026</pub-id><pub-id pub-id-type="pmcid">PMC11297375</pub-id></mixed-citation></ref><ref id="prp270080-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp270080-cit-0022"><string-name name-style="western"><given-names>S. S.</given-names><surname>Hasan</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Bal</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Baker</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Kow</surname></string-name>, and <string-name name-style="western"><given-names>M. U.</given-names><surname>Khan</surname></string-name>, &#8220;<article-title>Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010&#8208;2019</article-title>,&#8221; <source>Journal of Attention Disorders</source><volume>26</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>467</fpage>&#8211;<lpage>475</lpage>.<pub-id pub-id-type="pmid">33666114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1087054721997556</pub-id><pub-id pub-id-type="pmcid">PMC8785293</pub-id></mixed-citation></ref><ref id="prp270080-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp270080-cit-0023"><string-name name-style="western"><given-names>S. S.</given-names><surname>Hasan</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Aslam</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Islam</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Kow</surname></string-name>, and <string-name name-style="western"><given-names>Z. U. D.</given-names><surname>Babar</surname></string-name>, &#8220;<article-title>Metformin&#8208;Based Single Pill Drug Combinations for Type 2 Diabetes in Primary Care England: A Time Trend Analysis</article-title>,&#8221; <source>Primary Care Diabetes</source><volume>16</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>271</fpage>&#8211;<lpage>278</lpage>.<pub-id pub-id-type="pmid">35115253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcd.2022.01.008</pub-id></mixed-citation></ref><ref id="prp270080-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp270080-cit-0024"><string-name name-style="western"><given-names>S.</given-names><surname>Afzal</surname></string-name>, <string-name name-style="western"><given-names>S. T. R.</given-names><surname>Zaidi</surname></string-name>, <string-name name-style="western"><given-names>H. A.</given-names><surname>Merchant</surname></string-name>, <string-name name-style="western"><given-names>Z. U. D.</given-names><surname>Babar</surname></string-name>, and <string-name name-style="western"><given-names>S. S.</given-names><surname>Hasan</surname></string-name>, &#8220;<article-title>Prescribing Trends of Oral Anticoagulants in England Over the Last Decade: A Focus on New and Old Drugs and Adverse Events Reporting</article-title>,&#8221; <source>Journal of Thrombosis and Thrombolysis</source><volume>52</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>646</fpage>&#8211;<lpage>653</lpage>.<pub-id pub-id-type="pmid">33666824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11239-021-02416-4</pub-id><pub-id pub-id-type="pmcid">PMC7933373</pub-id></mixed-citation></ref><ref id="prp270080-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp270080-cit-0025"><string-name name-style="western"><given-names>G.</given-names><surname>Moulis</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sommet</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Durrieu</surname></string-name>, et&#160;al., &#8220;<article-title>Trends of Reporting of &#8216;serious'vs. &#8220;Non&#8208;serious&#8221; Adverse Drug Reactions Over Time: A Study in the French PharmacoVigilance Database</article-title>,&#8221; <source>British Journal of Clinical Pharmacology</source><volume>74</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>201</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">22257367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2012.04185.x</pub-id><pub-id pub-id-type="pmcid">PMC3394146</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>